Savient to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology...

Savient to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

EAST BRUNSWICK, N.J.--(Business Wire)--Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that
Christopher G. Clement, President and Chief Executive Officer, and Zeb
Horowitz M.D., Chief Medical Officer of Savient Pharmaceuticals, will
present a corporate update at the upcoming 2008 Merrill Lynch Global
Pharmaceutical, Biotechnology and Medical Device Conference that will
be held at the Grand Hyatt Hotel in New York.

The presentation is scheduled for 1:00 p.m. EST on Wednesday,
February 6th, 2008. For more information about Savient
Pharmaceuticals, Inc., please visit the company website at
www.savient.com.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals is a biopharmaceutical company engaged in
developing and distributing pharmaceutical products that target unmet
medical needs in both niche and broader markets. The Company's lead
product development candidate, Puricase(R) for treatment-failure gout,
has reported positive Phase 1 and 2 clinical data. Patient dosing in
the Phase 3 clinical studies began in June 2006; patient enrollment
was completed in March 2007; and the Phase 3 clinical studies were
completed in October 2007. Savient has licensed worldwide rights
related to Puricase (pegloticase) from Duke University and Mountain
View Pharmaceuticals, Inc. Pegloticase became the official generic
name for Puricase assigned by the USAN Council replacing the
previously used name of PEG-uricase. Savient's experienced management
team is committed to advancing its pipeline and expanding its product
portfolio by in-licensing late-stage compounds and exploring
co-promotion and co-development opportunities that fit the Company's
expertise in specialty pharmaceuticals and biopharmaceuticals with an
initial focus in rheumatology. Savient also manufactures and supplies
Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a
registered trademark of Mountain View Pharmaceuticals, Inc. Further
information on Savient can be accessed by visiting:
http://www.savient.com.

SVNT-G

Savient Pharmaceuticals, Inc.
Mary Coleman
Director, Investor Relations
information@savient.com
732-418-9300
or
Lippert/Heilshorn & Associates
Anne Marie Fields
afields@lhai.com
212-838-3777

Copyright Business Wire 2008